PET/CT and breast cancer

Area of Science:

• Nuclear medicine
• Oncology
• Radiology

Background:

• Positron emission tomography with [18F]fluoro-2-deoxy-D-glucose (FDG-PET) has advanced cancer patient management.
• Clinical interpretation of FDG-PET is challenging due to difficulties in anatomical localization and distinguishing physiological uptake from pathology.
• Visual correlation with morphological imaging (CT, MRI) improves PET accuracy but faces clinical integration challenges.

Purpose of the Study:

• To evaluate the impact of combined PET/CT on breast cancer diagnosis compared to PET alone.
• To assess PET/CT's role in disease re-staging, treatment monitoring, preoperative staging, and primary diagnosis of breast cancer.
• To explore the utility of PET/CT in radiotherapy planning for breast cancer patients.

Main Methods:

• Review of existing studies on PET/CT in breast cancer management.
• Comparison of diagnostic performance between PET/CT and PET alone.
• Evaluation of PET/CT's capabilities in localization, staging, monitoring, and radiotherapy planning.

Main Results:

• Combined PET/CT offers improved localization and interpretation of FDG uptake compared to PET alone.
• PET/CT demonstrates potential benefits across various aspects of breast cancer management, including staging and monitoring.
• Few studies have focused on PET/CT for breast cancer, but its technical advantages suggest significant clinical relevance.

Conclusions:

• PET/CT enhances the accuracy of FDG uptake interpretation in breast cancer diagnosis.
• The combined modality shows promise for improving breast cancer staging, treatment monitoring, and radiotherapy planning.
• Further research is warranted to fully elucidate the clinical impact of PET/CT in comprehensive breast cancer care.